In the latest trading session,, 0.39 million Protalix BioTherapeutics Inc (AMEX:PLX) shares changed hands as the company’s beta touched -0.22. With the company’s most recent per share price at $1.43 changed hands at -$0.11 or -7.14% at last look, the market valuation stands at $113.83M. PLX’s current price is a discount, trading about -116.78% off its 52-week high of $3.10. The share price had its 52-week low at $0.82, which suggests the last value was 42.66% up since then. When we look at Protalix BioTherapeutics Inc’s average trading volume, we note the 10-day average is 1.88 million shares, with the 3-month average coming to 1.10 million.
Protalix BioTherapeutics Inc (AMEX:PLX) trade information
Instantly PLX was in red as seen in intraday trades today. With action 5.93%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 16.26%, with the 5-day performance at 5.93% in the green. However, in the 30-day time frame, Protalix BioTherapeutics Inc (AMEX:PLX) is -10.06% down. Looking at the short shares, we see there were 1.19 million shares sold at short interest cover period of 1.7 days.
Protalix BioTherapeutics Inc (PLX) estimates and forecasts
Year-over-year growth is forecast to reach 8.44% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 13.49M. 2 analysts are of the opinion that Protalix BioTherapeutics Inc’s revenue for the current quarter will be 17.72M. The company’s revenue for the corresponding quarters a year ago was 13.3M and 17.84M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 1.37%. The estimates for the next quarter sales put growth at -0.64%.
The 2025 estimates are for Protalix BioTherapeutics Inc earnings to increase by 250.00%.
PLX Dividends
Protalix BioTherapeutics Inc is expected to release its next quarterly earnings report on 2025-May-09.
Protalix BioTherapeutics Inc (AMEX:PLX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 10.39% of Protalix BioTherapeutics Inc shares while 10.78% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 12.03%. There are 10.78% institutions holding the Protalix BioTherapeutics Inc stock share, with MILLENNIUM MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 1.1106% of the shares, roughly 0.81 million PLX shares worth $0.95 million.
RENAISSANCE TECHNOLOGIES LLC holds the second largest percentage of outstanding shares, with 1.1016% or 0.8 million shares worth $0.94 million as of 2024-06-30.
Among Mutual Funds, the top two as of May 31, 2025 were SEI INSTITUTIONAL MANAGED TRUST-SIMT TAX-MANAGED SMALL/MID CAP FUND and Unified Series Trust-AUER GROWTH FUND . With 272.94 shares estimated at $0.4 million under it, the former controlled 0.34% of total outstanding shares. On the other hand, Unified Series Trust-AUER GROWTH FUND held about 0.25% of the shares, roughly 200.0 shares worth around $0.29 million.
